For further prognostic evaluation and clinical decision-making, breast cancer can be classified into three subgroups based on immunohistochemical staining results for ER, PR, and HER2: HR-positive/HER2negative (HR+/HER2, ~70%), HER2positive (HER2+, ~1520%), and triple-negative breast cancer [TNBC, HR-negative (HR-), HER2, ~15%]
Verified Clinical Reputation Ruby K 19 Jan 2026 Norin Hanifi 19 Jan 2026 Dominique Heslop 13 Jan 2026 lloyda221 06 Jan 2026 Mane Authority 06 Jan 2026 Victor Contreras Guerra 4 months ago A A 5 months ago harris jan 3 months ago Independent Patient Feedback Verify on Google Reviews Clinical Note: To protect patient confidentiality while maintaining educational clarity, some anatomical illustrations on this site utilise medically-verified, AI-generated models
Does the body cease to produce its own glutathione in case I supplement it on a daily basis
The FDA-approved starting dose is 2.5 mg